^
Association details:
Biomarker:RAS wild-type
Cancer:Colorectal Cancer
Drug:Vectibix (panitumumab) (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
12/03/2007
Excerpt:
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC)...as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Evidence Level:
Sensitive: A1 - Approval
Published date:
12/03/2007
Excerpt:
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC)...in first-line in combination with Folfox or Folfiri.
Secondary therapy:
FOLFOX; FOLFOXIRI
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC):...As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy....In combination with FOLFOX for first-line treatment.
Secondary therapy:
FOLFOX
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Published date:
10/25/2022
Excerpt:
In RAS-wt patients not previously treated with an anti-EGFR mAb, treatment with ChT (FOLFIRI or irinotecan) and cetuximab or panitumumab could be considered for left-sided colon tumours [II, C].
Secondary therapy:
FOLFIRI; irinotecan
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation

Excerpt:
...Efficacy variables: • PFS, separately for each group of patients with defined low-frequency RAS mutation (Groups A, B and C) • OS, separately for each group of patients with defined low-frequency RAS mutation (Groups A, B and C) • ETS, separately for each group of patients with defined low-frequency RAS mutation (Groups A, B and C) • DpR, separately for each group of patients with defined low-frequency RAS mutation (Groups A, B and C) • Retrospectively determined optimal cut-off frequency for low-frequency RAS mutation leading to RR, PFS and OS in ranges comparable to that of RAS-wildtype first-line patients treated with panitumumab in combination with chemotherapy • Prospective analysis of tumor marker level evolution (CEA and CA 19-9) Safety variables: • Type, incidence, relatedness, and severity of adverse events according to NCI CTCAE version 5.0...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Excerpt:
...RAS wild-type tested in...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Excerpt:
...- Wild-type KRAS tumor status confirmed by an Amgen approved central laboratory or an experienced laboratory (local laboratory) per local regulatory guidelines using a validated test method...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Excerpt:
...- KRAS wild-type colorectal cancer...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases

Excerpt:
...Only patients with K-RAS wild-type cancers are eligible....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

VECTIBIX PLUS OXALIPLATIN-BASED ADJUVANT TREATMENT OF RECTAL CANCER

Excerpt:
...All the following must be met• Written Informed consent• Adult patients with resected rectal cancer, stage 2 and 3• Wild-type kRAS tumor status• Age > 18• Adequate PS <2• Resection of rectal cancer preceded by chemo-irradiation; there should be at least 3 weeks of postoperative recovery allowed before initiation of adjuvant treatment. ...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

Excerpt:
...- KRAS-wildtype of the tumor...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Excerpt:
...- Subjects with wild-type KRAS tumor status confirmed by an Amgen approved central laboratory assessment or an experienced local laboratory assessment of archival tumor tissue (preferably from the primary tumor);...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy

Excerpt:
...- Subjects with wild-type KRAS tumor status confirmed by central laboratory assessment of paraffin-embedded tumor tissue from the primary tumor or metastasis....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Multizentrische Phase 2-Studie zur neoadjuvanten Radiochemotherapie in Kombination mit Panitumumab bei lokal fortgeschrittenem Rektumkarzinom mit Nachweis von KRAS Wild-Typ (NEOREC-1-Studie)

Excerpt:
...o Histologically confirmed, potentially resectable rectal adenocarcinoma staged as uT3/4 N0/1 by endosonography or cT3/4 by MRI of the pelvis with or without local lymph node metastases.o Wild-type KRAS.o ECOG-performance status 0 or 1.o Age ≥ 18 years.o Laboratory requirements:- Haematology: Leucocyte count > 3,000/mm³, neutrophil count ≥1.5x109/L, hemoglobin ≥ 8 g/dL, platelet count ≥100x109/L.- Hepatic Function: Total bilirubin ≤ 1.5 time the upper normal limit (UNL), ASAT ≤ 2.5xUNL in absence of liver metastases or ≤ 5xUNL in presence of liver metastases, ALAT ≤ 2.5xUNL in absence of liver metastases or ≤ 5xUNL in presence of liver metastases- Renal Function: Creatinine clearance ≥50 mL/min or serum creatinine ≤1.5xUNL- Metabolic Function: Magnesium ≥ lower limit of normal, Calcium ≥ lower limit of normal.o Negative ß-HCG-serum pregnancy test (females of child bearing potential).o Willing to use double-barrier contraception during study and for 6 months after the end of treatment. ...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Initial therapy with FOLFOX-4 plus panitumumab followed by maintenance therapy with 5-FU/LV plus panitumumab or single-agent panitumumab in patients with metastatic colorectal cancer and absence of mutations of RAS genes. Terapia iniziale con FOLFOX-4 e panitumumab seguito da terapia di mantenimento con 5-fluorouracile/leucovorin e panitumumab o solo panitumumab in pazienti affetti da carcinoma colorettale metastatico e assenza di mutazione dei geni RAS.

Excerpt:
...Histologically or cytologically confirmed adenocarcinoma of the colon or rectum, with RAS wild-type status;6. ...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

Excerpt:
...- Unresectable, advanced or recurrent colorectal cancer with wild-type KRAS gene...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Excerpt:
...Progression-free Survival`Overall Survival in Participants With Wild-type RAS`Progression Free Survival (PFS) in Participants With Wild-type RAS`Objective Response Rate`Objective Response Rate in Participants With Wild-type RAS`Number of Participants With Adverse Events (AEs)`Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)

Excerpt:
...Histologically or cytologically confirmed adenocarcinoma of the colon or rectum, with RAS wild-type status; 6....
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Preoperative Panitumumab and Radiotherapy in Rectal Cancer

Excerpt:
...- Wild-type KRAS...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer

Excerpt:
...Patients with wild-type RAS (KRAS and NRAS) status of metastatic colorectal cancer treatment with panitumumab according to label...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)

Excerpt:
...- Wild-type RAS (determined by an accredited local laboratory, if...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Excerpt:
...Tumor tissue must reveal wild-type KRAS expression (i.e....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer

Excerpt:
...- Wild-type KRAS....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

KRAS Wild-type Metastatic Colorectal Cancer Trial

Excerpt:
...Tumor is KRAS wild-type....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer

Excerpt:
...Progression-free survival rate at 6 months for subjects with KRAS wild-type tumours...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Phase II study of pre-operative treatment with external radiotherapy plus panitumumab in operable locally advanced rectal cancer (favourable and intermediate prognostic group) (RaP Study/STAR-03) Studio di fase II sul trattamento pre-operatorio con radioterapia esterna e panitumumab in pazienti con tumore del retto in stadio localmente avanzato, operabile, a prognosi favorevole o intermedia (Studio RaP/STAR-03)

Excerpt:
...Histologically diagnosis of adenocarcinoma of the mid-low rectum (within 12 cm from the anal verge); KRAS wild type; age ≥18 years; Karnofsky performance status of ≥70 at study entry; clinical stage T3 N- M0 or cT2-T3 N+ M0 - CRM; hemoglobin ≥ 9 g/dl; neutrophils ≥ 1.5 x 10^9/L; platelets ≥ 100 x 10^9/L; bilirubin level < 1.5 ULN; ASAT and ALAT <= 2.5 x ULN; serum creatinine < 1.5 x ULN; magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal; effective contraception for both, male and female patients if the risk of conception exists; signed and dated written informed consents Diagnosi Istologica di adenocarcinoma del retto medio-basso (entro 12 cm dal margine anale); KRAS wild-type; Età≥ 18 anni; Karnofsky performance status ≥70 all'inizio dello studio; stadio clinico T3 N-M0 o CT2-T3 N + M0 - CRM; emoglobina ≥ 9 g / dl; neutrofili ≥1,5 x 10^9 / L; piastrine ≥ 100 x 10^9 / L; livello di bilirubina <1,5 ULN; ASAT e ALAT <= 2,5 x ULN; creatinina sierica < 1,5 x ULN; magnesio ≥ limite inferiore del normale; calcio ≥ limite inferiore del normale; contraccettivo efficace per entrambi, pazienti maschi e femmine se il rischio di concepimento esiste; consenso informato scritto firmato e datato....
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Excerpt:
...Patients classified as KRAS/NRAS wild-type by KRAS/NRAS testing....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

Excerpt:
...- RAS wild-type tested in...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer

Excerpt:
...- Molecular testing showing RAS wild-type in colorectal carcinoma cells...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Excerpt:
...- Histologically confirmed all RAS wild type....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Excerpt:
...- Wild-type KRAS tumor status...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Excerpt:
...Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-Resistant MET High Subjects with Locally Advanced or Metastatic Colorectal Cancer with Wild-Type KRAS...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

Excerpt:
...Histologically proven diagnosis of colorectal cancer with wildtype RAS and BRAF status in certified laboratories; 3....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)

Excerpt:
...- a metastatic colorectal cancer, histologically proved, wild-type RAS 2....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

Excerpt:
...Wild-type RAS tumour status confirmed in liquid biopsies before starting second-line treatment 6....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer

Excerpt:
...- Patients with Formalin-Fixed, Paraffin-Embedded tissue RAS wild type colorectal cancer at diagnosis, who had initial clinical benefit [complete response, partial response or stable disease] during first line irinotecan-based or oxaliplatin-based chemotherapy in combination with cetuximab or panitumumab,...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line

Excerpt:
...- Adult (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFOX or FOLFIRI plus panitumumab or FOLFOX or FOLFIRI plus cetuximab as upfront treatment as per clinical practice...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Excerpt:
...- RAS wild-type tumor...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer

Excerpt:
...- Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR

Excerpt:
...- RAS WT tumor documented before study enrolment as per routine laboratory finding...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma

Excerpt:
...Participants classified as KRAS wild-type....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer

Excerpt:
...Participants classified as KRAS/NRAS wild-type** by KRAS/NRAS testing*....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Excerpt:
...- Tumor expressing wild-type Kras mutations...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Excerpt:
...- Wild-type KRAS expressing mCRC from the primary tumor or metastasis....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer

Excerpt:
...To estimate the PFS by DP immunohistochemistry (IHC) expression in patients with wild-type KRAS mCRC treated with panitumumab and mFOLFOX6. ...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

Excerpt:
...- Histological diagnosis of colorectal cancer that is KRAS wild type...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases

Excerpt:
...- Wild Type KRAS status...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

622P - Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE

Published date:
10/16/2023
Excerpt:
VALIDATE is a multicenter, non-interventional study evaluating real-world effectiveness, safety and quality of life in pts with RAS WT mCRC receiving 1L PAN plus FOLFIRI/FOLFOX….The IA2 showed favorable effectiveness for PAN plus FOLFIRI/FOLFOX in the total population and in all mCCS risk groups in clinical routine in Germany and Austria.
Secondary therapy:
FOLFIRI; FOLFOX
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study

Published date:
08/09/2023
Excerpt:
Patients with previously untreated, wild-type Rat sarcoma virus (RAS), and resectable CLM were included. Preoperative four and postoperative eight cycles of panitumumab and folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) were administered….Panitumumab and FOLFIRI as perioperative therapy for resectable CLM result in a radiological objective response rate in 65.7% of patients with a manageable grade 3 diarrhea rate of 14.3%. Median PFS was 13.2 months, and the 24-month OS rate was 73.3%.
DOI:
https://doi.org/10.3389/fonc.2023.1231600
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)

Published date:
07/11/2023
Excerpt:
Male patients derived a significant benefit from the addition of Pmab to maintenance treatment with regard to PFS [hazard ratio (HR) 0.63; 95% confidence interval (CI) 0.45-0.88; P = 0.006]...In the PanaMa trial, the addition of Pmab to maintenance treatment of RAS wild-type mCRC with FU/FA improved the outcome in terms of the primary endpoint (PFS) particularly in male patients.
Secondary therapy:
5-fluorouracil + leucovorin calcium
DOI:
10.1016/j.esmoop.2023.101568
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: an individual patient data pooled analysis of randomized clinical trials

Published date:
06/19/2023
Excerpt:
We performed an individual patient data pooled analysis of Valentino, Panama, MACRO-2, COIN-B trials including RAS wild-type mCRC patients who received first-line therapy with FOLFOX plus panitumumab or cetuximab...Overall, 123, 185, 210 patients received maintenance with 5-FU/LV, anti-EGFR, 5-FU/LV+anti-EGFR, respectively. Median PFS was 5.6, 6.0 and 9.0 (P=0.009) and OS was 25.7, 24.0 and 28.0 months (P=0.134) in 5-FU/LV, anti-EGFR and 5-FU/LV+anti-EGFR arms, respectively....This pooled analysis including four randomized phase II supports the use of 5-FU/LV plus anti-EGFR as preferred maintenance regimen.
Secondary therapy:
5-fluorouracil + leucovorin calcium
DOI:
https://doi.org/10.1016/j.ejca.2023.112945
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer A Phase 2 Randomized Clinical Trial

Published date:
05/18/2023
Excerpt:
In this randomized clinical trial of 62 Italian patients with refractory RAS wild-type MCRC, panitumumab plus trifluridine-tipiracil increased PFS at 6 and 12 months compared with trifluridine-tipiracil alone.
Secondary therapy:
trifluridine/tipiracil
DOI:
10.1001/jamaoncol.2023.0655
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial

Published date:
04/18/2023
Excerpt:
Median progression-free survival for panitumumab vs bevacizumab was 13.1 vs 11.9 months, respectively, for those with left-sided tumors (HR, 1.00; 95% CI, 0.83-1.20) and 12.2 vs 11.4 months overall (HR, 1.05; 95% CI, 0.90-1.24). Response rates with panitumumab vs bevacizumab were 80.2% vs 68.6%, respectively, for left-sided tumors (difference, 11.2%; 95% CI, 4.4%-17.9%) and 74.9% vs 67.3% overall (difference, 7.7%; 95% CI, 1.5%-13.8%)....Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, compared with bevacizumab, to standard first-line chemotherapy significantly improved overall survival in those with left-sided tumors and in the overall population.
Secondary therapy:
mFOLFOX6
DOI:
10.1001/jama.2023.4428
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis

Published date:
11/14/2022
Excerpt:
Meta-analysis showed that EGFR inhibitors significantly prolonged the overall survival (OS) [HR = 0.83, 95%CI (0.73, 0.94), P = 0.003] and overall response rate (ORR) [RR = 1.11, 95%CI (1.05, 1.18), P = 0.0003] compared to VEGF inhibitors in wild-type KRAS/RAS mCRC patients... ​Our study showed that EGFR inhibitors were superior to VEGF inhibitors in wild-type KRAS/RAS mCRC patients, especially in patients with first-line treatment.
Secondary therapy:
Chemotherapy
DOI:
10.1080/14737140.2022.2147512
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)

Published date:
10/25/2022
Excerpt:
In patients with RAS wild-type metastatic colorectal cancer...The overall DpR in all patients was 56.5%. DpR of induction therapy (42.5%) accounted for the largest proportion (75.2%) of the overall DpR. While greater DpR to induction therapy was significantly associated with prolonged PFS (HR 0.70, 95% CI 0.52-0.93, p = 0.013) and OS (HR 0.38, 95% CI 0.28-0.51, p < 0.001)...DpR to induction therapy accounted for three quarters of the total tumour shrinkage potentially suggesting that FOLFOX plus Pmab can be de-escalated following induction without substantially compromising efficacy.
Secondary therapy:
FOLFOX
DOI:
10.1016/j.ejca.2022.09.011
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results

Published date:
08/10/2022
Excerpt:
The median progression-free survival (PFS) and overall survival (OS) were 6.0 [95% CI, 5.4-10.0] and 17.5 months (95% CI, 13.8-24.3), respectively….Panitumumab showed favorable OS in frail or elderly patients with RAS wild-type CRC and no prior exposure to chemotherapy.
DOI:
10.1093/oncolo/oyac145
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).

Published date:
06/27/2022
Excerpt:
Overall response rate was 33% (arm A) vs. 7.7% (arm B). Six-month progression-free survival rate was 66.7% (arm A) and 38.5% (arm B). Median progression-free survival was 11.0 months (arm A) and 4.0 months (arm B)...The BEYOND study suggests a meaningful benefit of P-FOLFIRI beyond progression to P-FOLFOX in metastatic colorectal cancer patients with WT RAS status selected by LB.
Secondary therapy:
FOLFIRI
DOI:
10.1007/s12094-022-02868-x
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.

Published date:
05/26/2022
Excerpt:
...previously untreated RAS/BRAF wt mCRC pts, were randomized to a control arm (A) receiving FOLFIRI/PANI...At a median follow-up of 18 months (IQR: 10-26), median PFS OT was 12.6 months (95% CI: 9.0-16.1) in arm A and 17.6 months (95% CI: 7.5-27.8) in arm B with a 1 year PFSOT rate of 51.7% and 61.3%, respectively. ORR (arm A/B) was 64/56%....The primary endpoint of the study was met with the intermittent FOLFIRI-PANI strategy producing a long PFS...
Secondary therapy:
FOLFIRI
DOI:
10.1200/JCO.2022.40.16_suppl.3503
Trial ID: